<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37545739</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1466-1861</ISSN><JournalIssue CitedMedium="Internet"><Volume>2023</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Mediators of inflammation</Title><ISOAbbreviation>Mediators Inflamm</ISOAbbreviation></Journal><ArticleTitle>Urinary Modified C-Reactive Protein is Closely Associated with Tubulointerstitial Lesions in Lupus Nephritis.</ArticleTitle><Pagination><StartPage>6107911</StartPage><MedlinePgn>6107911</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6107911</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2023/6107911</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Modified C-reactive protein (mCRP) is known to be involved in the upregulation and amplification of the local inflammatory response. This study investigated the circulating and local levels of mCRP and their relevance to clinicopathological features in patients with lupus nephritis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Ninety-five patients with renal biopsy-proven lupus nephritis and 30 normal controls were enrolled in this study. Plasma and urinary mCRP were screened by enzyme-linked immunosorbent assay (ELISA). The renal deposition of mCRP was detected by immunohistochemistry and immunofluorescence staining. A human proximal tubular epithelial cell line (HK2 cells) was incubated with purified IgG from lupus nephritis, and the production of CRP by HK2 cells was further evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Plasma and urinary levels of mCRP increased significantly in patients with lupus nephritis compared with normal controls (<i>P</i> = 0.013, <i>P</i> &lt; 0.001, respectively). The urinary mCRP levels were associated with interstitial inflammatory cell infiltration (<i>r</i>&#x2009;=&#x2009;0.514, <i>P</i> &lt; 0.001) and interstitial fibrosis (<i>r</i>&#x2009;=&#x2009;0.270, <i>P</i> = 0.008). The ROC-AUC of the urinary mCRP levels for diagnosing tubulointerstitial lesions was 0.766. The urinary mCRP levels were closely associated with poor outcomes (HR: 1.204, 95% CI: 1.029-1.409, <i>P</i> = 0.020). However, no correlations were found of the plasma mCRP levels with clinicopathological data or the prognosis of lupus nephritis. CRP was mostly deposited in the renal tubules in patients with lupus nephritis, and the expression of CRP was significantly correlated with tubulointerstitial lesion indices. Immunofluorescence staining showed that mCRP could colocalize with IgG in tubules. Lupus nephritis-derived IgG could induce CRP production by HK2 cells.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Urinary mCRP levels were significantly increased, and urinary mCRP might be a biomarker for tubulointerstitial lesions in patients with lupus nephritis. Renal CRP could be produced by tubular epithelial cells after stimulation by lupus nephritis-derived IgG, and the local presence of mCRP might play a critical role in the development of tubulointerstitial lesions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Mo Yuan et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Mo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5372-0106</Identifier><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Yunnan University, Kunming, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Affiliated Hospital of Yunnan University, Second People's Hospital of Yunnan Province, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiao-Ling</ForeName><Initials>XL</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Cell Activities and Stress Adaptations, School of Life Sciences, Lanzhou University, Lanzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8139-5758</Identifier><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Peking University International Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ming-Hui</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Renal Division, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Units of Diagnosis and Treatment of Immune-Mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mediators Inflamm</MedlineTA><NlmUniqueID>9209001</NlmUniqueID><ISSNLinking>0962-9351</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declared that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37545739</ArticleId><ArticleId IdType="pmc">PMC10403327</ArticleId><ArticleId IdType="doi">10.1155/2023/6107911</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yu F., Haas M., Glassock R., Zhao M.-H. Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nature Reviews Nephrology . 2017;13:483&#x2013;495. doi: 10.1038/nrneph.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneph.2017.85</ArticleId><ArticleId IdType="pubmed">28669995</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Dell J. R., Hays R. C., Guggenheim S. J., Steigerwald J. C. Tubulointerstitial renal disease in systemic lupus erythematosus. Archives of Internal Medicine . 1985;145(11):1996&#x2013;1999. doi: 10.1001/archinte.1985.00360110066018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1985.00360110066018</ArticleId><ArticleId IdType="pubmed">4062450</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes M. F., Mardones C., Xipell M., et al. The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. Journal of Nephrology . 2021;34:1897&#x2013;1905. doi: 10.1007/s40620-021-01007-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-021-01007-z</ArticleId><ArticleId IdType="pubmed">33721269</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F., Wu L.-H., Tan Y., et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney International . 2010;77(9):820&#x2013;829. doi: 10.1038/ki.2010.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2010.13</ArticleId><ArticleId IdType="pubmed">20182417</ArticleId></ArticleIdList></Reference><Reference><Citation>Broder A., Mowrey W. B., Khan H. N., et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: a retrospective cohort study. Seminars in Arthritis and Rheumatism . 2018;47(4):545&#x2013;551. doi: 10.1016/j.semarthrit.2017.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2017.07.007</ArticleId><ArticleId IdType="pmc">PMC5927553</ArticleId><ArticleId IdType="pubmed">28803673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema I. M., Wilhelmus S., Alpers C. E., et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney International . 2018;93(4):789&#x2013;796. doi: 10.1016/j.kint.2017.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.11.023</ArticleId><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurlimann J., Thorbecke G. J., Hochwald G. M. The liver as the site of C-reactive protein formation. Journal of Experimental Medicine . 1966;123(2):365&#x2013;378. doi: 10.1084/jem.123.2.365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.123.2.365</ArticleId><ArticleId IdType="pmc">PMC2138142</ArticleId><ArticleId IdType="pubmed">4379352</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepys M. B., Hirschfield G. M. C-reactive protein: a critical update. The Journal of Clinical Investigation . 2003;111(12):1805&#x2013;1812. doi: 10.1172/JCI200318921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200318921</ArticleId><ArticleId IdType="pmc">PMC161431</ArticleId><ArticleId IdType="pubmed">12813013</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrive A. K., Gheetham G. M. T., Holden D., et al. Three dimensional structure of human C-reactive protein. Nature Structural &amp; Molecular Biology . 1996;3:346&#x2013;354. doi: 10.1038/nsb0496-346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsb0496-346</ArticleId><ArticleId IdType="pubmed">8599761</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji S.-R., Wu Y., Zhu L., et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRPm. The FASEB Journal . 2006;21(1):284&#x2013;294. doi: 10.1096/fj.06-6722com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-6722com</ArticleId><ArticleId IdType="pubmed">17116742</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiele J. R., Habersberger J., Braig D., et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation . 2014;130(1):35&#x2013;50. doi: 10.1161/CIRCULATIONAHA.113.007124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.007124</ArticleId><ArticleId IdType="pubmed">24982116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajab I. M., Hart P. C., Potempa L. A. How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression. Frontiers in Immunology . 2020;11 doi: 10.3389/fimmu.2020.02126.2126</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.02126</ArticleId><ArticleId IdType="pmc">PMC7511658</ArticleId><ArticleId IdType="pubmed">33013897</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu P.-C., Lin S., Yang X.-W., et al. C-reactive protein enhances activation of coagulation system and inflammatory response through dissociating into monomeric form in antineutrophil cytoplasmic antibody-associated vasculitis. BMC Immunology . 2015;16 doi: 10.1186/s12865-015-0077-0.10</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-015-0077-0</ArticleId><ArticleId IdType="pmc">PMC4357196</ArticleId><ArticleId IdType="pubmed">25879749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond D. J., Jr, Singh S. K., Thompson J. A., et al. Identification of acidic pH-dependent ligands of pentameric C-reactive protein. Journal of Biological Chemistry . 2010;285(46):36235&#x2013;36244. doi: 10.1074/jbc.M110.142026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.142026</ArticleId><ArticleId IdType="pmc">PMC2975246</ArticleId><ArticleId IdType="pubmed">20843812</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Potempa L. A., El Kebir D., Filep J. G. C-reactive protein and inflammation: conformational changes affect function. Biological Chemistry . 2015;396(11):1181&#x2013;1197. doi: 10.1515/hsz-2015-0149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/hsz-2015-0149</ArticleId><ArticleId IdType="pubmed">26040008</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams R. D., Moran J. A., Fryer A. A., et al. Monomeric C-reactive protein in serum with markedly elevated CRP levels shares common calcium-dependent ligand binding properties with an in vitro dissociated form of C-reactive protein. Frontiers in Immunology . 2020;11 doi: 10.3389/fimmu.2020.00115.115</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00115</ArticleId><ArticleId IdType="pmc">PMC7010908</ArticleId><ArticleId IdType="pubmed">32117266</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan Y.-Y., Yao Y.-M. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Frontiers in Immunology . 2018;9 doi: 10.3389/fimmu.2018.01302.1302</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01302</ArticleId><ArticleId IdType="pmc">PMC6008573</ArticleId><ArticleId IdType="pubmed">29951057</ArticleId></ArticleIdList></Reference><Reference><Citation>Enocsson H., Gullstrand B., Eloranta M.-L., et al. C-reactive protein levels in systemic lupus erythematosus are modulated by the interferon gene signature and CRP gene polymorphism rs1205. Frontiers in Immunology . 2021;11 doi: 10.3389/fimmu.2020.622326.622326</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.622326</ArticleId><ArticleId IdType="pmc">PMC7876312</ArticleId><ArticleId IdType="pubmed">33584722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Li H.-Y., Li W., et al. An ELISA assay for quantifying monomeric C-reactive protein in plasma. Frontiers in Immunology . 2018;9 doi: 10.3389/fimmu.2018.00511.511</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00511</ArticleId><ArticleId IdType="pmc">PMC5857914</ArticleId><ArticleId IdType="pubmed">29593741</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabs W. J., L&#xf6;gering B. A., Gerke P., et al. The kidney as a second site of human C-reactive protein formation in vivo. European Journal of Immunology . 2003;33(1):152&#x2013;161. doi: 10.1002/immu.200390018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/immu.200390018</ArticleId><ArticleId IdType="pubmed">12594844</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwedler S. B., Guderian F., Dammrich J., Potempa L. A., Wanner C. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrology Dialysis Transplantation . 2003;18(11):2300&#x2013;2307. doi: 10.1093/ndt/gfg407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfg407</ArticleId><ArticleId IdType="pubmed">14551357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis &amp; Rheumatism . 1997;40(9) doi: 10.1002/art.1780400928.1725</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Y., Tan Y., Li Y., et al. Pentraxin 3 is closely associated with tubulointerstitial injury in lupus nephritis: a large multicenter cross-sectional study. Medicine . 2016;95(3) doi: 10.1097/MD.0000000000002520.e2520</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000002520</ArticleId><ArticleId IdType="pmc">PMC4998266</ArticleId><ArticleId IdType="pubmed">26817892</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang M. H., Socher S. A., Larson M. G., Schur P. H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis &amp; Rheumatism . 1989;32(9):1107&#x2013;1118. doi: 10.1002/anr.1780320909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anr.1780320909</ArticleId><ArticleId IdType="pubmed">2775320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bombardier C., Gladman D. D., Urowitz M. B., et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis &amp; Rheumatism . 1992;35(6):630&#x2013;640. doi: 10.1002/art.1780350606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780350606</ArticleId><ArticleId IdType="pubmed">1599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan M., Tan Y., Li J., Yu X., Zhang H., Zhao M. Urinary sediments could differentiate endocapillary proliferative lupus nephritis and endocapillary proliferative IgA nephropathy. International Immunopharmacology . 2021;90 doi: 10.1016/j.intimp.2020.107122.107122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107122</ArticleId><ArticleId IdType="pubmed">33199236</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin H. A., III, Muenz L. R., Joyce K. M., Antonovych T. T., Balow J. E. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney International . 1984;25:689&#x2013;695. doi: 10.1038/ki.1984.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1984.75</ArticleId><ArticleId IdType="pubmed">6482173</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin H. A., III, Boumpas D. T., Vaughan E. M., Balow J. E. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney International . 1994;45:544&#x2013;550. doi: 10.1038/ki.1994.70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1994.70</ArticleId><ArticleId IdType="pubmed">8164443</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L.-L., Tan Y., Song D., et al. Anti-complement factor H autoantibodies may be protective in lupus nephritis. Clinica Chimica Acta . 2020;508:1&#x2013;8. doi: 10.1016/j.cca.2020.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.05.005</ArticleId><ArticleId IdType="pubmed">32387092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Nie L.-M., Pang Y., et al. Composite urinary biomarkers to predict pathological tubulointerstitial lesions in lupus nephritis. Lupus . 2018;27(11):1778&#x2013;1789. doi: 10.1177/0961203318788167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318788167</ArticleId><ArticleId IdType="pubmed">30020021</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita C. M., Ying S. C., Hugli T. E., et al. Elucidation of a protease-sensitive site involved in the binding of calcium to C-reactive protein. Biochemistry . 1989;28(25):9840&#x2013;9848. doi: 10.1021/bi00451a044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi00451a044</ArticleId><ArticleId IdType="pubmed">2692716</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y., Yu F., Yang H., Chen M., Fang Q., Zhao M.-H. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Human Immunology . 2008;69(12):840&#x2013;844. doi: 10.1016/j.humimm.2008.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2008.09.006</ArticleId><ArticleId IdType="pubmed">18852001</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q.-Y., Li H.-Y., Fu G., Yu F., Wu Y., Zhao M.-H. Autoantibodies against C-reactive protein influence complement activation and clinical course in lupus nephritis. Journal of The American Society of Nephrology . 2017;28(10):3044&#x2013;3054. doi: 10.1681/ASN.2016070735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2016070735</ArticleId><ArticleId IdType="pmc">PMC5619952</ArticleId><ArticleId IdType="pubmed">28566480</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung S., Tsang R. C. W., Sun Y., Leung J. K. H., Chan T. M. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. Journal of the American Society of Nephrology . 2005;16(11):3281&#x2013;3294. doi: 10.1681/ASN.2004110917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2004110917</ArticleId><ArticleId IdType="pubmed">16192422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinloch A. J., Chang A., Ko K., et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis &amp; Rheumatology . 2014;66(12):3359&#x2013;3370. doi: 10.1002/art.38888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38888</ArticleId><ArticleId IdType="pmc">PMC4264660</ArticleId><ArticleId IdType="pubmed">25306868</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H.-J., Saxena R., Zhao M.-H., Parodis I., Salmon J. E., Mohan C. Lupus nephritis. Nature Reviews Disease Primers . 2020;6 doi: 10.1038/s41572-019-0141-9.7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y., Tang J., Mok M. Y., Chan A. W. K., Wu A., Lau C. S. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis &amp; Rheumatism . 2003;48(10):2888&#x2013;2897. doi: 10.1002/art.11237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.11237</ArticleId><ArticleId IdType="pubmed">14558095</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>